Table 1.
Characteristics of Participants Aged 2–19 Years Who Newly Initiated Integrase Strand Inhibitor–Based Regimens, January 2011 to March 2019 (N = 38)
| Characteristic | No. (%) |
|---|---|
| Demographic characteristics | |
| Age, y, median (IQR) | 15 (11–16) |
| Age category, y | |
| 2–12 | 15 (39) |
| 13–19 | 23 (61) |
| Male sex | 14 (37) |
| Non–Hispanic black | 36 (95) |
| HIV infection and ART characteristics | |
| Perinatally acquired HIV | 35 (92) |
| Undetectable HIV VL (<20 copies/mL) at INSTI initiation | 16 (42) |
| Nadir CD4 count, cells/µL, median (IQR) | 225 (54–376) |
| CD4 count at INSTI initiation, cells/µL, median (IQR) | 697.5 (503–862) |
| CD4 %, median (IQR) | 30.5 (19–34) |
| Follow-up time on INSTIs, d, median (IQR) | 527.5 (477–625) |
| Prior ART regimen | |
| PI based | 26 (68) |
| NNRTI based | 6 (16) |
| EFV | 3 (8) |
| NVP | 3 (8) |
| NRTI only | 4 (10) |
| NNRTI/PI based | 1 (3) |
| ART naive | 1 (3) |
| Initiated INSTI | |
| DTG | 28 (74) |
| EVG | 7 (18) |
| RAL | 3 (8) |
| Regimen with TAF | 9 (24) |
| Anthropometric characteristics | |
| Height, m, median (IQR) | 1.60 (1.52–1.65) |
| Height-for-age z score, median (IQR) | –0.50 (–1.21 to –0.05) |
| Weight, kg, median (IQR) | 57.61 (49.44–64.86) |
| Weight-for-age z score, median (IQR) | 0.41 (–0.47 to 1.11) |
| BMI-for-age z score, median (IQR) | 0.86 (–0.06 to 1.26) |
| BMI, kg/m2, median (IQR) | 22.68 (20.11–25.80) |
| BMI category, kg/m2 | |
| Underweight (<18.5) | 3 (8) |
| Normal (18.5–<24.9) | 21 (55) |
| Overweight (25–29.9) | 13 (34) |
| Obese (≥30) | 1 (3) |
| Prescription for weight-influencing medication | 2 (5) |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; DTG, dolutegravir; EFV, efavirenz; EVG, elvitegravir; HIV, human immunodeficiency virus; INSTI, integrase strand transfer inhibitor; IQR, interquartile range; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor; RAL, raltegravir; TAF, tenofovir alafenamide fumarate; VL, viral load.